What is Nevolat®?
Nevolat® is the brand name of your medicine, the active ingredient of which is liraglutide.1
Nevolat® is the brand name of your medicine, the active ingredient of which is liraglutide.1
Nevolat® is a GLP1-RA (glucagon-like peptide-1 receptor agonist) that helps people lose weight, when they also exercise regularly and eat healthy foods.1 Losing weight can have many benefits for your overall health.2
How does Nevolat® work?
Nevolat® is a weight loss medicine. It is similar to a natural hormone in our bodies called glucagon-like peptide-1 (GLP-1), which is released from the gut after a meal and tells us we’re no longer hungry.1
The same thing happens when you take Nevolat® medicine. It acts in the brain to help control your appetite, making you feel fuller and less hungry.1
Changes to lifestyle, including diet and exercise, are a key part of the Nevolat® weight loss treatment plan. It is important to make these healthy changes while you are using Nevolat®.1
Who can take Nevolat®?
You should only continue to take Nevolat® if you have lost a certain amount of weight in the first 3 months of taking the medicine. You will have regular appointments with your doctor to check on progress.1
Adults (18 years+)
In adults with obesity (a BMI of ≥30 kg/m2) or who have health problems from being overweight (a BMI of ≥27 kg/m2), Nevolat® can be given alongside regular exercise and eating healthy foods. Possible health problems may include diabetes, high blood pressure, abnormal levels of fats in the blood or breathing problems during sleep (known as obstructive sleep apnoea).1
Adolescents (12 years+)
In adolescents (≥ 12 years old) who have obesity or excess body weight (more than 60 kg), Nevolat® can be given alongside regular exercise and eating healthy foods to help with weight loss.1
1. Nevolat® (liraglutide) Patient Information Leaflet. Available from: https://www.medicines.org.uk/emc/product/100226/pil Accessed December 2024.
2. NHS UK. Better Health. Available from https://www.nhs.uk/better-health/lose-weight/ Accessed December 2024.
000697610 | December 2024